ETERNAL's 8th and final newsletter is jam packed with information on where you can find our more about the exciting range of results and achievements attained across the whole project as reaches its formal conclusion at the end of August 2026. Latest results, new publications, awrds nominations, final dissemination activity and useful links. It's all here!

A range of posters and impact summary inforgraphics presented at ETERNAL's July 2026 Final Dissmeination Event are available now as downloadable pdf files.

ETERNAL's recent final official project dissemination event provided project partners and external guests alike an opportunity to reflect upon and celebrate notable progress made during four years of collaborative research and scale-up for sustainable development of pharmaceutical manufacture, use and disposal, along with notable contributions towards building the the EU’s knowledge base informing environmental risk and ecotoxicity assessemts of pharamceuticals on the one hand and policy development on the other.

We are excited to share the news that ETERNAL's "remarkable contribution to standardization through the development of two CWAs" has been recognised by a nomination in the Project Award category for the Standards+Innovation Awards 2026.

We are delighted to share the news that, as of 15th April 2026, the EU Standards related Collaborative Workshop Agreement CWA 18361:2026 - Methodology for Early-Stage Sustainability Assessment and Efficient Energy by Design is available and freely accessible to anyone on the CEN open-access CWA download area.

ETERNAL's latest white paper publication provides an evaluation of how to embed early-stage thinking about safety and sustainability in process (re)design as applied to an industrial case study involving five different options for re-engineering acetone from water solvent recovery in part of a commercial API manufacturing process.

The ETERNAL Horizon Europe Research and Innovation Action has just made seven industrial case study summaries publically available. The easily-read two-page documents provide a concise summary of the key features, progress to date, and further steps involved as several of the project's applied research efforts start to yield fruit in an at or near industrial ready state.

This newsletter, the sixth since the ETERNAL project started, provides ample opportunities to dig deeper into both the project’s research illuminating the environmental risks surrounding pharmaceutical manufacture and positive responses from the industry to minimize the risks through technological innovation and standardization for less impactful, more efficient, sustainable and safe by design processes.